A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO-2 Trial)

June 02, 2021
https://clinicaltrials.gov/ct2/show/NCT04223193
Parkinson Disease
Principal Investigator: Peter A Le Witt, MD
Movement Disorder, Parkinson Disease,  Parkinsonian Disorders, Nervous System Diseases
Accepting Participants